LEADER 01674nam  2200457   450 
001 9910715097803321
005 20221025204920.0
035   $a(CKB)4100000011920005
035   $a(NjHacI)994100000011920005
035   $a(OCoLC)1162822833
035   $a(EXLCZ)994100000011920005
100   $a20221025d2019      uy             0
101 0 $aeng
135   $aur|||||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aPharmacotherapy for the treatment of cannabis use disorder $ea systematic review /$fKarli Kondo
210  1$aWashington, District of Columbia :$cDepartment of Veterans Affairs (US),$d2019.
215   $a1 online resource (84 pages) $cillustrations
225 1 $aEvidence-Based Synthesis Program (Series)
300   $a"February 2019."
320   $aIncludes bibliographical references.
410  0$aEvidence-based synthesis program (Series)
517   $aPharmacotherapy for the treatment of cannabis use disorder 
606   $aChemotherapy
606   $aOutcome assessment (Medical care)
606   $aMarijuana abuse
615  0$aChemotherapy.
615  0$aOutcome assessment (Medical care)
615  0$aMarijuana abuse.
676   $a615.58
700   $aKondo$b Karli$01353458
712 02$aUnited States.$bDepartment of Veterans Affairs.$bHealth Services Research and Development Service,
712 02$aPortland VA Medical Center.$bEvidence-based Synthesis Program Center.
801  0$bNjHacI
801  1$bNjHacl
906   $aBOOK
912   $a9910715097803321
996   $aPharmacotherapy for the treatment of cannabis use disorder$93291170
997   $aUNINA